Conference abstract · 23 May 2019
Conference abstractPublished 25 May 2023
Obesity Pharmacotherapy
Cairo University, Egypt
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Antiobesity pharmacotherapy is one strategy to offset the adaptive changes in appetite and energy expenditure that occur with weight loss and to improve adherence to lifestyle interventions. According to the 2013 American College of Cardiology/Amer-ican Heart Association/The Obesity Society's guideline for the management of overweight and obesity in adults and the Endocrine Society's clinical practice guidelines on the pharmacologic management of obesity, pharmacotherapy for obesity can be considered if patients have a body mass index (BMI) of 30 kg/m? or greater or a BMI of 27 kg/m~ or greater with weight-related comorbidities, such as hypertension, dyslipidemia, type 2 diabetes, and obstructive sleep apnea. As obesity is a chronic disease, most antiobesity medications are approved is Phentermine was approved by the FDA in 1959 and has been the most commonly prescribed medication for obesity in the United States. ORLISTAT Before 2012, the only antiobesity medicine approved for long-term use was orlistat, which was approved by the FDA in 1999. PHENTERMINE/TOPIRAMATE EXTENDED RELEASE In 2012, the FDA approved phentermine/topiramate ER for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity. LORCASERIN Lorcaserin, a selective serotonin (5-hydroxytryptamine [5HT)-2C receptor agonist, was approved by the FDA in 2012 as a long-term treatment of obesity. NALTREXONE SUSTAINED RELEASE/BUPROPION Naltrexone/bupropion was approved for the treatment of obesity in 2014. Bupropion is a dopamine and norepinephrine reuptake inhibitor that was FDA approved as an antidepressant in 1989.. LIRAGLUTIDE 3.0 MG Liraglutide 3.0 mg was the second agent approved by the FDA in 2014 for chronic weight management. PRACTICAL TIPS FOR TREATMENT important for primary care providers to be familiar with the pharmacotherapy available to patients who are unable to lose weight and sustain weight loss with lifestyle interventions alone. There are 2 important questions to ask when prescribing an antiobesity medication to patients. The first question is whether there are undesirable side effects, contrain-dications, or drug-drug interactions. For example, avoid orlistat if patients have a condition predisposing to malabsorption and avoid phentermine and phentermine/ topiramate ER if patients have unstable coronary disease. The second question is whether any of the medications could improve another symptom or condition. Pharmacotherapy should not be prescribed in the absence of behavioral counseling focusing on diet, physical activity, and lifestyle modifications, which are the cornerstones of weight management.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 28 Nov 2017
Obesity and pharmacotherapy: Looking ahead for chronic weight management and weight regain prevention
Perspective · 30 Dec 2024
Pharmacotherapy for Obesity: Evaluating the Efficacy and Safety of New Weight Loss Medications
Commentary · 27 Sep 2024
Pharmacogenomics and Personalized Approaches in Obesity Pharmacotherapy
Opinion · 4 Apr 2024
Pharmacotherapy for Pediatric Obesity: A Vital Component of Comprehensive Management
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectObesity & Weight Management
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Basma Mandour”
